Anthony Cleary (@Anthonycleary2) profile picture
Aurora, Ontario
Joined April 2016
Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)Photo by Anthony Cleary (@Anthonycleary2)
$HIMS vs $SHOP. Same stage of growth through 21 quarters. Notice a) Hims recent quarterly revenue outpacing $SHOP. b) $HIMS market cap well below $SHOP at the time. TWENTY ONE QUARTERS. More than 5 years of consistent growth. @AndrewDudum @Aktiediplomaten
2
2
11
1,312
BOA issues apology for predicting $HIMS would have Q4 revenues of $435-$447k. They add, "please don't listen to our price targets, because, obviously, we either have alternative motives or don't know what we are doing"?
4
460
Anthony Cleary retweeted
Thank you again to @AndrewDudum for committing to answering two questions from the $HIMS retail community Here were the top questions from Hims House Pumped for earnings later today! 🤞
6
10
3
236
51,457
Anthony Cleary retweeted
At the core of $hims is a simple yet powerful idea: we use precision medicine to personalize the delivery of existing, clinically studied medications. We are not bypassing the regulatory process or creating new drugs. We focus on delivering better care through personalization. Period. Precision medicine is about using the right tools for the right patient at the right time – and it gets better with strategic innovation. Our holistic approach means increasingly integrating lab work, provider engagement, patient choice, and clinical data ensure that personalization is thoughtful, safe, evidence-based, and patient-centric. We believe this approach will ultimately drive better clinical outcomes. We’re committed to integrity and transparency. We won’t claim improved efficacy until the data substantiates it. And we show our quality and safety process. We take a logical approach that lets patients and providers draw their own conclusions because we know that patients, not pharmaceutical profits, should drive our health care system. Obviously, critical to personalization is the need to compound medication. Under our current health system, we do this in two very specific circumstances: 1. Drug shortages: We ensure patients have continued access at affordable prices. While Big Pharma charges in the thousands, we fill the gap by giving people access at prices that can be in the hundreds. 2. Clinical necessity: We enable personalized treatment when commercially available options don’t meet individual patient needs, whether in dosages, administration, or the need for additional ingredients. We do this because it is the right thing to do for the patient. We don’t compound every medication, even if we believe it would help our profits. For example, we never chose to compound tirzepatide, even though it could have been profitable. Why not? In part, its wide range of commercially available dosages support a lower side effect profile that reduces the likelihood an individual will require alteration to meet their needs. We do compound semaglutide. Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs. We’re also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have “capacity limitations” and “expected continued periodic supply constraints and related drug shortage notifications.” We know that demand remains high, despite the $1200+ Novo Nordisk charges in the US compared to the $135-$300 it charges in its native Denmark. Since we have spoken out on the need to fix today’s “Stuck & Sick” health care system, we’ve seen Big Pharma react by questioning the need for affordable compounded options or purposely scaring regular Americans by making broad strokes about the “safety” of compounded medicines. Our commitment is clear: patient safety and regulatory integrity, and using precision, personalization, and necessity—not convenience—to align with the highest standards of care. Our goal: empower patients, empower providers, provide comprehensive choices tailored to the individual, and do it the right way. Precision medicine is about making existing treatments work better for individuals. We’re proud to stand for thoughtful innovation, not shortcuts. Holistic care means incorporating more than medicine into lifestyle changes that lead to better outcomes. At the end of the day, better care is comprehensive – and personal.
241
83
1,799
459,802
$HIMS short squeeze continues...and its just getting started.
16
430
Anthony Cleary retweeted
$HIMS chart is misleading. Its still a 10B company doing revenue like its a 100B company.
1
1
221
Anthony Cleary retweeted
$hims squeeze it
1
1
138
They also produced the ad in house!!!! No outside agency.
According to EDO, $HIMS money were well spent. #1 engagement in pharma #5 engagement overall All publicity is good publicity. edo.com/feature/super-bowl-2…
4
249
Anthony Cleary retweeted
According to EDO, $HIMS money were well spent. #1 engagement in pharma #5 engagement overall All publicity is good publicity. edo.com/feature/super-bowl-2…
4
1
39
3,679
Even though $HIMS is up 77% YTD the short interest keeps climbing Honestly it could get wild
3
5
1
42
12,160
Anthony Cleary retweeted
Replying to @TheLongInvest
A positive catalyst before the earnings release could be alternative data of credit card spending on Bloomberg. If they will demonstrate SB Ad success, price may rally to 50. $HIMS
7
1
1
8
4,070
Anthony Cleary retweeted
$HIMS reminds me of $NFLX in its early days. When Netflix first started, it didn’t invent anything new—it simply repackaged existing products in a more convenient way. DVDs already existed, and so did movie rentals, but Netflix took that model and made it better, more accessible, and frictionless. People doubted it at first. Blockbuster laughed at the idea that people would abandon physical stores for a mail-order service. Then streaming came along, and Netflix once again took an existing concept—on-demand video—and turned it into a juggernaut. Now, look at where Netflix is today. It’s not just distributing content—it’s creating it. The company that once mailed out DVDs now produces blockbuster original series and films, investing billions into content that never would have existed without them. In the same way, Hims & Hers isn’t inventing new drugs today. It’s taking existing medications and making them more accessible, removing the bureaucracy, friction, and stigma that keep people from getting treatment. Just like Netflix, Hims is building trust with consumers by offering something familiar—but doing it in a way that feels revolutionary. Eventually, Hims won’t just be repackaging medications. As it grows, it will have the resources to invest in research, develop its own pharmaceuticals, and potentially even become a pharmaceutical company itself. Just like Netflix went from licensing content to creating its own award-winning originals, Hims could go from distributing existing treatments to innovating new ones. This is how disruption happens. It starts with making something easier, more accessible, and consumer-friendly. Then, once the company is big enough and has the capital, it starts building what never existed before. Netflix did it with content. Hims & Hers could do it with healthcare. And just like people didn’t see Netflix’s potential early on, many are underestimating what Hims can become.
44
76
14
772
130,300
Anthony Cleary retweeted
Replying to @Dr_Crossroads
Ok let’s go guys we know the deal let’s squeeze these guys get them to cover at 100$ maybe ? $hims dca until 60$ Growing at a crazy rate
1
2
243
Anthony Cleary retweeted
Replying to @calleymeans
I'd love that! I'm a huge fan of @drmarkhyman and think we'd have a great, nuanced conversation. Mark helped saved my father's life when I was a young kid and my Dad had stage4 cancer and severe metabolic dysfunction. If the three of us aren't able to find common alignment on how to reverse the epidemic of obesity in America I'm not sure anyone will.
7
2
1
41
2,293
Anthony Cleary retweeted
🚨 BREAKING: $HIMS SHORT INTEREST HITS NEW RECORD - 58.2 MILLION SHARES - 33% OF FLOAT 🤯 ABSOLUTE INSANITY
31
28
11
396
88,484
Anthony Cleary retweeted
Replying to @himshouse
Institutions can loan out their shares to short right? Just that there is 30% shorts which is crazy… don’t get why they don’t cover yet… can go parabolic if this continues
1
1
686
$HIMS short squeeze continues. These highlighted areas don't look good for the short sellers. What is their plan? How much more $ are they willing to lose?
1
11
866
Anthony Cleary retweeted
$HIMS Hers is officially HIGHER THAN Hims on the App Store medical rankings Hers is #2 Hims is #4 The first time this has happened since we started tracking the data 🤯
9
14
4
356
21,926
Anthony Cleary retweeted
$HIMS Controversy sells! The ad is working. The app is currently being downloaded by hundreds of thousands of people nationwide. 🙏🙏🙏
1
10
698
$HIMS looks like SB ad was a great success. More Short squeeze anyone?
This quoted post is unavailable.
2
1
28
1,431